This website is no longer being updated. For the latest updates on COVID-19, including vaccines and treatments, please visit www.cdc.gov/coronavirus. Healthcare professionals, please visit www.phe.gov/emergency/events/COVID19/Pages/default.aspx and www.covid19treatmentguidelines.nih.gov.
WHAT ARE ACTIV CLINICAL TRIALS FOR COVID-19?
In April 2020, the National Institutes of Health (NIH) launched the public-private partnership, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). ACTIV’s goal is to discover safe and effective treatments and vaccines for COVID-19. ACTIV clinical trials explore COVID-19 treatments for patients who:
- Have mild to moderate symptoms of COVID-19, but have not been hospitalized
- Are hospitalized with moderate to severe COVID-19 infection
- Were hospitalized due to COVID-19 and are now recovering at home
HEALTHCARE PROFESSIONALS’ ROLES IN ACTIV
ACTIV is led by healthcare professionals who previously pioneered essential public health initiatives that have shaped our current guidelines for patient care. It is absolutely critical to continue fervent efforts in research as COVID-19 variants continue to emerge and the COVID-19 pandemic evolves. Healthcare providers are the leaders of the COVID-19 public health crisis and can help patients the most.
There are several hundred ACTIV clinical trial sites across the United States and in every region. This gives everyone more potential options for COVID-19 treatment and strengthens data validity across patient populations. Thousands of participants have already participated in ACTIV and more participants enroll daily.
STAGES OF COVID-19 IN ACTIV STUDIES
ACTIV has clinical trial options testing different treatments for each stage of COVID-19 based upon presenting symptoms, from mild to critical in severity, and within inpatient and outpatient settings. Interested participants are pre-screened further to determine eligibility.
For more assistance with clinical trial enrollment and eligibility questions, you or your patient can call 1-877-414-8106 or visit the ACTIV clinical trial options for COVID-19 patients page to use the live chat feature.
INSIDE ACTIV CLINICAL TRIALS
Everyone who participates in ACTIV clinical trials receives the same standard of care, as in the NIH recommended guidelines for treatment of COVID-19. Participants could receive the investigational therapy or the placebo (control group), depending upon their randomization assignment.
ACTIV clinical trials are seeking further treatments and prevention for COVID-19, which includes testing classes of therapies that have been successfully used to treat other conditions and are now being considered for potential COVID-19 remedies. Monoclonal antibodies (mAbs), antivirals, and antithrombotics are some of the classes already being tested. However, medications that can be self-administered orally or by inhalation are part of an initiative to find an easier, more accessible option for COVID-19 patients to reduce symptoms. ACTIV clinical trials include some studies for patients in the hospital (inpatient) and studies for people at home (outpatient).
Researchers monitor all participants for safety during and after the clinical trial period with assessments in person and potentially by telephone or virtually. Just as enrollment in any clinical trial is a choice, participants may choose to discontinue enrollment at any time. Clinical researchers advocate for continuity in patient care and encourage all participants to continue their healthcare journey with their original trusted healthcare providers upon clinical trial conclusion.
HOW HEALTHCARE PROFESSIONALS CAN HELP PATIENTS ENROLL IN ACTIV
Educational toolkits are also available for you to download and give to your healthcare staff and patients. You can also contact Combat COVID’s call center at 1-877-414-8106 and speak with an information specialist about clinical trials near you.